v3.24.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenues    
Royalty $ 1,369 $ 2,911
Service 175,476 92,488
Product 598,457 210,993
Total Revenues 775,302 306,392
Operating Expenses    
Research and development 19,551,523 15,332,989
General and administrative 10,368,314 10,177,229
Sales and marketing 6,843,160 6,576,246
Total Operating Expenses 36,762,997 32,086,464
Operating Loss (35,987,695) (31,780,072)
Other Income (Expenses)    
Grant income 214,451 1,229,425
Loss on disposal of fixed assets (15,843) 0
Interest income 93,324 125,265
Interest expense (221,622) (173,087)
Gain on change in fair value of warrant liability 240,311 0
Total Other Income 310,621 1,181,603
Net Loss (35,677,074) (30,598,469)
Net Loss attributable to Non-Controlling Interest 357,996 329,676
Net Loss attributable to VolitionRx Limited Stockholders (35,319,078) (30,268,793)
Other Comprehensive Income (Loss)    
Foreign currency translation adjustments 16,843 78,771
Net Comprehensive Loss $ (35,660,231) $ (30,519,698)
Net Loss Per Share - Basic and Diluted attributable to VolitionRx Limited Stockholders $ (0.50) $ (0.55)
Weighted Average Shares Outstanding    
- Basic and Diluted 71,234,565 55,350,401

Source

PDF HTML 10-K Filing
ZIP XLS HTML XBRL